TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37144820

Group type: EXPERIMENTAL
Intervention: CushMed (16 patients treated with stable cortisol-lowering drug dosage)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CushSurg (13 patients cured by pituitary surgery)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CushBla (15 patients receiving hydrocortisone after bilateral adrenalectomy)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CushMed (16 patients)
Number of subjects: 44
Study: 37145134

Group type: EXPERIMENTAL
Intervention: Nd:YAG/Er:YAG dual laser therapy (4 treatments, 1-2 months apart)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topical steroid application (6 months)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nd:YAG/Er:YAG dual laser therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nd:YAG/Er:YAG dual laser therapy and Topical steroid application
Number of subjects: 66
Study: 37145169

Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: paxalisib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ONC201 and paxalisib (combination)
Number of subjects: 0
Study: 37145174

Group type: EXPERIMENTAL
Intervention: Endoscopic management (EG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgical management (SG)
Number of subjects: 78
Study: 37145268

Group type: EXPERIMENTAL
Intervention: Self-rated fall risk assessment tool (KaatumisSeula® [KS])
Number of subjects: 384
Study: 37145600

Group type: EXPERIMENTAL
Intervention: Home-based, individualized, and goal-oriented rehabilitation program (8 sessions over 4 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care in municipality
Number of subjects: 120
Study: 37145975

Group type: EXPERIMENTAL
Intervention: Zanubrutinib co-administered with rifabutin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 13
Study: 37146180

Group type: EXPERIMENTAL
Intervention: Iodine intake of 235 (133, 401) μg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Iodine intake >400 μg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Long-term iodine intake >400 μg/day
Number of subjects: 29
Study: 37146219

Group type: COMPARATOR
Intervention: Parenting interventions
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Financial empowerment programme
Number of subjects: 1925
Study: 37146227

Group type: EXPERIMENTAL
Intervention: pembrolizumab + axitinib (PEM+AXI)
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: nivolumab + ipilimumab (NIV+IPI)
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: lenvatinib + pembrolizumab (LEN+PEM)
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: pazopanib (PAZ)
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: cabozantinib (CAB)
Number of subjects: 15177
Study: 37146263

Group type: EXPERIMENTAL
Intervention: Vulnerable participants with MDS
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: MDS patients with low, intermediate, and high-risk disease
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Vulnerable MDS participants
Number of subjects: 449

Group type: COMPARATOR
Intervention: Overall HRQoL among patients with cytopenias
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Vulnerability vs disease risk in MDS
Number of subjects: 449
Study: 37146444

Group type: EXPERIMENTAL
Intervention: StayWell text messaging intervention (60-day program based on cognitive behavioral therapy)
Number of subjects: 398
Study: 37146530

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises
Number of subjects: 52
Study: 37146752

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg administered intravenously every 4 weeks for four doses, followed by up to nine doses of durvalumab monotherapy every 4 weeks for up to 12 months or until disease progression
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 78
Study: 37146761

Group type: EXPERIMENTAL
Intervention: Highest tertile of dietary micronutrient adequacy (85.8%-97.7%)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Lowest tertile of dietary micronutrient adequacy (40.1%-78.7%)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: 1-SD increment in minerals and vitamins adequacy
Number of subjects: 1461
Study: 37146874

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral therapy (ABBT) plus treatment-as-usual (TAU)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) only
Number of subjects: 240
Study: 37147083

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) administration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wearable biosensors monitoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms
Number of subjects: 60
Study: 37147124

Group type: EXPERIMENTAL
Intervention: Short-term air pollution exposure (specifically nitrogen dioxide - NO2)
Number of subjects: 449
Study: 37147201

Group type: EXPERIMENTAL
Intervention: 3-antigen vaccine (PreHevbrio™)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Single-antigen vaccine (Engerix-B)
Number of subjects: 100000
Study: 37147298

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serial circulating tumor DNA sampling
Number of subjects: 41
Study: 37147301

Group type: EXPERIMENTAL
Intervention: Midostaurin added to intensive chemotherapy in late group (2016-2020)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Midostaurin in NPM1 mutated patients (n=151)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Midostaurin in low and high FLT3-ITD allelic ratio patients
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (naive patients)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Midostaurin in late group (2016-2020)
Number of subjects: 227
Study: 37147320

Group type: EXPERIMENTAL
Intervention: Head-down position (HDP) -20° Trendelenburg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 96
Study: 37147462

Group type: EXPERIMENTAL
Intervention: Remote digital postoperative wound monitoring for 30-days postoperatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Remote digital postoperative wound monitoring
Number of subjects: 200
Study: 37147496

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 3
Study: 37147587

Group type: EXPERIMENTAL
Intervention: Moving Well intervention (peer coach behavioral intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staying Well (attention control group)
Number of subjects: 0
Study: 37147635

Group type: EXPERIMENTAL
Intervention: Baseline pain severity (NRS score)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Higher baseline pain
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Baseline frailty
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Participants transitioning to frailty over one year
Number of subjects: 1179
Study: 37147638

Group type: EXPERIMENTAL
Intervention: Movement control exercise with specific breathing techniques (SBTs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Movement control exercise without specific breathing techniques (SBTs)
Number of subjects: 30
Study: 37147642

Group type: EXPERIMENTAL
Intervention: Oral dronabinol (BX-1) once daily before bedtime for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dronabinol (BX-1)
Number of subjects: 0
Study: 37147645

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 1999
Study: 37147667

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral treatment (ICBT)
Number of subjects: 4
Study: 37147690

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT II) in low-NED subgroup (n=56)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo in low-NED subgroup (n=48)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT II) in high-NED subgroup (n=107)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo in high-NED subgroup (n=110)
Number of subjects: 321
Study: 37147708

Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants experiencing sexual violence
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants experiencing physical violence 5 times or more in < 6 months
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants using illicit drugs in the last month
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants reporting higher levels of internalized stigma
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Depression in the absence of the SAVA syndemic factors
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: SAVA syndemic factors (substance use and violence) among non-depressed FSW
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Joint experience of depression and SAVA syndemics
Number of subjects: 1384
Study: 37147725

Group type: EXPERIMENTAL
Intervention: Rapid outreach following unsuppressed virus
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Rapid outreach following missed pharmacy refill collection
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Rapid outreach following missed doses as detected by an electronic adherence monitoring device
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Weekly check-in texts
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Enhanced peer support
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Combination of adherence monitoring and support components
Number of subjects: 512

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 512
Study: 37147739

Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS) administered by caregivers under remote supervision.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham control (placebo) group receiving a non-active intervention.
Number of subjects: 40
Study: 37147857

Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37147864

Group type: EXPERIMENTAL
Intervention: Pilates-based telerehabilitation (Pilates-TR)
Number of subjects: 30
Study: 37147930

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring (HTM) plus urinary peptidomic profiling (UPP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Home blood pressure telemonitoring (HTM) alone
Number of subjects: 144
Study: 37148183

Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy (PAP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia plus positive airway pressure (CBT-I+PAP)
Number of subjects: 45
Study: 37148240

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 59
Study: 37148249

Group type: EXPERIMENTAL
Intervention: Litifilimab (monoclonal antibody against BDCA2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37148266

Group type: EXPERIMENTAL
Intervention: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo
Number of subjects: 114

Group type: COMPARATOR
Intervention: SRP + oral hygiene instructions (Control)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo (in subjects with diabetes)
Number of subjects: 114
Study: 37148373

Group type: EXPERIMENTAL
Intervention: Symptom monitoring application for 8 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 222
Study: 37148375

Group type: EXPERIMENTAL
Intervention: Upper airway ultrasound (US)
Number of subjects: 50
Study: 37148395

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Practice Quitting
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Countering Emotional Behaviors
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall (Study 2)
Number of subjects: 48
Study: 37148474

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg or 150 mg
Number of subjects: 84
Study: 37148485

Group type: EXPERIMENTAL
Intervention: Risdiplam (Evrysdi)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Theoretical dual CYP3A-FMO3 substrates
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Refinement of FMO3 ontogeny in the risdiplam model
Number of subjects: 525
Study: 37148497

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 396

Group type: COMPARATOR
Intervention: Antimuscarinic agents
Number of subjects: 396
Study: 37148580

Group type: EXPERIMENTAL
Intervention: Age < 70 years
Number of subjects: 3686

Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 3686
Study: 37148652

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Participant-reported homework completion (within BATA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Clinician-reported homework completion (within BATA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Total homework completion (between-person effect)
Number of subjects: 73
Study: 37148831

Group type: EXPERIMENTAL
Intervention: Heated high-flow nasal cannula (HFNC) therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 18
Study: 37148899

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 526

Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 526
Study: 37149000

Group type: EXPERIMENTAL
Intervention: IN-PEACE care coordination intervention (n=99)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care (n=102)
Number of subjects: 201
Study: 37148999

Group type: EXPERIMENTAL
Intervention: SafERteens BI + Text Messaging (TM)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SafERteens BI + remote Health Coach (HC)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Continued intervention condition (maintenance)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Minimized condition (stepped down)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Continued condition (maintenance)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intensified condition (stepped up)
Number of subjects: 400
Study: 37149056

Group type: EXPERIMENTAL
Intervention: Sertraline plus olanzapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 80
Study: 37149149

Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine
Number of subjects: 15
Study: 37149257

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (exercise-based rehabilitation program consisting of two weekly sessions of physical exercise for 8 weeks and one educational session)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 211
Study: 37149443

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19) vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37149458

Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 0
Study: 37149595

Group type: EXPERIMENTAL
Intervention: Wearable accelerometers for measuring and monitoring motor behaviour during CareToy-Revised training
Number of subjects: 0
Study: 37149647

Group type: EXPERIMENTAL
Intervention: Left portal vein shunt with 8-mm Viatorr stent
Number of subjects: 130

Group type: COMPARATOR
Intervention: Right portal vein shunt with 8-mm Viatorr stent
Number of subjects: 130
Study: 37149670

Group type: EXPERIMENTAL
Intervention: Relevance Factor Variational Autoencoder (RF-VAE)
Number of subjects: 0
Study: 37149701

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (2.5, 5 mg)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: High-dose tamoxifen (10, 20 mg)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Tamoxifen (any dose)
Number of subjects: 1440
Study: 37149709

Group type: EXPERIMENTAL
Intervention: Intensive, individualized lifestyle intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 37149818

Group type: EXPERIMENTAL
Intervention: pIPOM
Number of subjects: 187

Group type: COMPARATOR
Intervention: sIPOM
Number of subjects: 187
Study: 37149821

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10131
Study: 37149930

Group type: EXPERIMENTAL
Intervention: MSC treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37150129

Group type: EXPERIMENTAL
Intervention: IPRGC lenses (spectacles blocking light wavelengths that stimulate IPRGCs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control lenses (standard lenses)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: IPRGC lenses
Number of subjects: 78
Study: 37150144

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment
Number of subjects: 501
Study: 37150147

Group type: EXPERIMENTAL
Intervention: Antibodies to gliadin (AGA IgG)
Number of subjects: 0
Study: 37150258

Group type: EXPERIMENTAL
Intervention: Fractionated brain radiation therapy (RT)
Number of subjects: 44
Study: 37150411

Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 141

Group type: COMPARATOR
Intervention: Oral intake
Number of subjects: 141

Group type: COMPARATOR
Intervention: NGT
Number of subjects: 141
Study: 37150797

Group type: EXPERIMENTAL
Intervention: Anthropometric method using index finger length to measure OVD (Sn-Me)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard method for measuring OVD
Number of subjects: 80
Study: 37150895

Group type: EXPERIMENTAL
Intervention: Extended-release melatonin (4 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate-release melatonin (4 mg)
Number of subjects: 18
Study: 37150952

Group type: EXPERIMENTAL
Intervention: Deucravacitinib (once-daily oral pill)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (inactive pill)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apremilast (twice-daily oral pill)
Number of subjects: 0
Study: 37150956

Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 0
Study: 37151084

Group type: EXPERIMENTAL
Intervention: Free dermal fat graft (FDFG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Superficial musculoaponeurotic system (SMAS) flap
Number of subjects: 78
Study: 37151105

Group type: EXPERIMENTAL
Intervention: 12-month testosterone replacement therapy (TRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 37151329

Group type: EXPERIMENTAL
Intervention: Psychosocial support services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV) and validated questionnaires
Number of subjects: 0
Study: 37151571

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation and auricular acupuncture (CIH therapies)
Number of subjects: 149

Group type: COMPARATOR
Intervention: GW Health Education (GWHE) program
Number of subjects: 149
Study: 37151894

Group type: EXPERIMENTAL
Intervention: Urine cystatin C (uCysC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urine neutrophil gelatinase-associated lipocalin (uNGAL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urine kidney injury molecule 1 (uKIM-1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CS-AKI+/FO+ infants
Number of subjects: 40
Study: 37152307

Group type: EXPERIMENTAL
Intervention: Combined dance and yoga intervention (8 months duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37152360

Group type: EXPERIMENTAL
Intervention: vixotrigine 200 mg BID
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: vixotrigine 350 mg BID
Number of subjects: 265

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 265
Study: 37152361

Group type: EXPERIMENTAL
Intervention: INTEP-AR model (large Infarct, NIHSS score, Thrombolysis, Endovascular treatment, Pneumonia, brain Atrophy, and Recanalisation)
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Risk score based on the INTEP-AR model
Number of subjects: 2183
Study: 37152362

Group type: EXPERIMENTAL
Intervention: Combined MDA of ivermectin, albendazole, and azithromycin
Number of subjects: 7292

Group type: COMPARATOR
Intervention: Ivermectin and albendazole MDA followed by azithromycin MDA
Number of subjects: 7292

Group type: COMPARATOR
Intervention: Azithromycin MDA (stand-alone)
Number of subjects: 7292
Study: 37152367

Group type: EXPERIMENTAL
Intervention: Saline irrigation (100 ml saline pulse irrigation after cholangiography)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 180
Study: 37152546

Group type: EXPERIMENTAL
Intervention: Revision ACL autograft reconstruction
Number of subjects: 184

Group type: COMPARATOR
Intervention: Primary ACL autograft reconstruction
Number of subjects: 184
Study: 37152602

Group type: EXPERIMENTAL
Intervention: VR-VET (20 sessions using a head-mounted display)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Waiting without VR-VET (4 weeks)
Number of subjects: 11
Study: 37152926

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (50 mmol/d sodium)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal sodium diet (100 mmol/d sodium)
Number of subjects: 50
Study: 37153086

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months
Number of subjects: 50